Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.
January saw Aimmune receive an FDA approval for Palforzia, a first for peanut allergy, alongside decisions for Blueprint Medicines and Horizon Therapeutics.
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Bayer and Merck & Co need Vitality data to breathe life into vericiguat, while Akero awaits its first big test with the Nash project AKR-001.
Pfizer's abrocitinib heads against Dupixent in atopic dermatitis, while Myovant hopes to raise its Spirits.
Enhertu gets an early thumbs up from the FDA – now decisions are due for Epizyme’s tazemetostat and Novo Nordisk's Rybelsus and Ozempic.
Axsome hopes to end 2019 on a high with its depression drug AXS-05 while Lilly’s pegilodecakin is unlikely to redeem itself in lung cancer.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Biolinerx’s BL-8040 needs to show improved responses in pancreatic cancer while investors will get a first look at Homology's HMI-102, a gene therapy for…